Jean-Marie Houle

Clinical Development Advisor

Dr. Houle is recognized for understanding drug development and how to step-up corporate growth and value. Jean-Marie brings clinical leadership to Madeleine with his expertise in pharmacology, pharmacokinetics and drug metabolism. He was previously VP/Managing Director of the Quintiles Phase I Unit at Guy's Hospital (London), transitioning assets through Phase I and Phase II Proof-Of-Concept (POC). Jean-Marie also worked for CPR Pharma Services of South Australia, a CRO that has been crucial for all of Madeleine's crucial assay development work. In Europe, Jean-Marie oversaw 475 employees and 500 beds on three sites as VP of Clinical Operations at Anapharm, a PharmaNet Company. At QLT Inc., he was a core team member that got worldwide approvals for Visudyne®, the first treatment for age-related macular degeneration, and contributed to transitioning pre-clinical concepts all the way to human POC. Numerous drug candidates have benefited from Jean-Marie's scientific and clinical expertise in various consultancy roles over the years. Jean-Marie graduated from Universite de Montreal with an M.Sc. and Ph.D. in Pharmaceutical Sciences.